Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer

Anavex Life Sciences (Nasdaq: AVXL) appointed Terrie Kellmeyer, PhD, as interim CEO effective May 6, 2026, following the departure of prior CEO Christopher Missling on April 30, 2026 and a request for his board resignation.

Rhea-AI Summary

Anavex Life Sciences (Nasdaq: AVXL) appointed Terrie Kellmeyer, PhD, as interim CEO effective May 6, 2026, following the departure of prior CEO Christopher Missling on April 30, 2026 and a request for his board resignation. Dr. Kellmeyer will prioritize clinical, regulatory and operational strategy for the company’s CNS pipeline, including lead candidate oral blarcamesine. The company said it has a strong cash balance with no long-term debt and expects to file a Form 12b-25 to extend its Form 10-Q filing for the quarter ended March 31, 2026. A conference call and webcast will be scheduled with further details.

Positive

• Interim CEO Terrie Kellmeyer brings ~30 years of drug development experience
• Company reports a strong cash balance with no long-term debt
• Clear strategic focus on lead candidate oral blarcamesine in early Alzheimer’s disease

Negative

• Form 12b-25 expected to delay filing of 10-Q for quarter ended March 31, 2026
• Departure of prior CEO and requested board resignation signals leadership transition risk

Argus May 6 session

-0.60% close to close Open Argus

Details

News Market Reaction – AVXL

On May 6, the day this news came out, AVXL closed 0.60% below the previous close.

Data tracked by StockTitan Argus for the May 6 session.

Market Context

This announcement combines a leadership transition with a planned Form 12b-25 to extend the filing d...

Analysis

This announcement combines a leadership transition with a planned Form 12b-25 to extend the filing date for the March 31, 2026 Form 10-Q. The board appointed an experienced clinical and regulatory executive as interim CEO, emphasizing continued focus on oral blarcamesine in early Alzheimer’s disease and broader CNS indications. Against a backdrop of earlier EU regulatory setbacks but supportive clinical data and a solid cash balance, investors may watch upcoming 10-Q details and subsequent regulatory interactions closely.

Key Figures

Net loss: $5.7M Prior net loss: $12.1M Operating expenses: $6.8M +5 more

Net loss

$5.7M

Three months ended Dec 31, 2025; narrower loss year-over-year

Prior net loss

$12.1M

Three months ended Dec 31, 2024 comparison

Operating expenses

$6.8M

Quarter ended Dec 31, 2025

Prior operating expenses

$13.6M

Quarter ended Dec 31, 2024

Capital raised

$36.3M

2025 at-the-market Sales Agreement proceeds

Cash & equivalents

$131.7M

Balance as of Dec 31, 2025

Prior cash & equivalents

$102.6M

Balance as of Sep 30, 2025

Stockholders’ equity

$126.6M

As of Dec 31, 2025

Historical Context

5 past events · Latest: Apr 14

5 events

1. Apr 14

   Scientific findings update

   24h Move

   +0.3%

   New biology linking autism and Alzheimer’s reinforced blarcamesine’s mechanistic rationale.

2. Apr 07

   Conference appearance

   24h Move

   +4.0%

   Announcement of Needham healthcare conference presentation highlighted ongoing investor outreach.

3. Mar 30

   Regulatory update

   24h Move

   +0.0%

   Company detailed EU withdrawal for blarcamesine and continued FDA and EU engagement.

4. Mar 25

   EU review setback

   24h Move

   -34.6%

   Withdrawal of EU marketing application after CHMP indicated no positive opinion expected.

5. Mar 23

   Clinical data update

   24h Move

   +9.4%

   New AD-004 data showed correlation between blarcamesine effect and brain volume preservation.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

form 12b-25, form 10-q, fda, ema, +1 more

5 terms

form 12b-25 regulatory

"The Company expects to file a Form 12b-25 to extend the filing date"

Form 12b-25 is a notice a publicly traded company files with the U.S. Securities and Exchange Commission when it cannot deliver a required periodic report (like a quarterly or annual financial report) on time. It explains the reason for the delay and gives the company a short, temporary window to finish the report without being marked as delinquent; investors watch it because late filings can signal accounting, operational, or control issues that may affect a company’s reliability and stock risk, much like a missed homework deadline can raise concerns about a student’s preparedness.

form 10-q regulatory

"extend the filing date of its Quarterly Report on Form 10-Q for the quarter"

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

fda regulatory

"while working closely with both the FDA and the EMA."

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

ema regulatory

"while working closely with both the FDA and the EMA."

Exponential moving average (EMA) is a type of trend line that smooths a stream of recent price data while giving more weight to the newest prices, similar to how a spotlight focuses more on what's happening now than what happened long ago. Investors use EMAs to see whether a stock’s short-term direction is changing, to compare fast and slow averages for momentum signals, and to help time entries, exits, and risk controls without overreacting to random day-to-day noise.

View in glossary

rett syndrome medical

"rare diseases, including Rett syndrome, and other central nervous system"

A rare genetic disorder that disrupts normal brain development in young children, most commonly girls, leading to slowed growth, loss of purposeful hand use, repetitive hand movements, motor problems, speech loss, and cognitive and breathing irregularities. Investors watch it because its severity and few treatment options create clear medical need and potential markets for therapies; think of it as a broken traffic signal in the brain that, if fixed, could restore many downstream functions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that its Board of Directors has appointed the Company’s former Senior Vice President of Clinical Development and current Senior Advisor, Terrie Kellmeyer, PhD, as Interim Chief Executive Officer. These appointments follow the departure of President and Chief Executive Officer Christopher Missling, PhD, MS, MBA, from the Company on April 30, 2026, and a request for his resignation from the Board of Directors. Dr. Kellmeyer will lead the Company’s next phase of growth that aligns with its strategic initiatives in enhancing the clinical development programs of the Company’s current portfolio.

“The Board has the utmost confidence in Dr. Kellmeyer’s ability to drive our clinical programs forward,” said Dr. Ma. “Terrie has extensive experience in senior leadership roles in the biotech and therapeutics space along with vast knowledge of our portfolio. We believe her expertise in clinical development, regulatory and medical affairs, and quality assurance makes her the right partner to advance our pipeline while working closely with both the FDA and the EMA.”

Dr. Terrie Kellmeyer is a seasoned pharmaceutical executive with nearly three decades of experience across the full spectrum of drug development. Dr. Kellmeyer has served as the Department Head for Global Regulatory Affairs, Clinical Development, Clinical Operations, Safety, Quality Assurance and Medical Affairs at numerous healthcare companies over the last 30 years. Dr. Kellmeyer is a proven strategic leader, which is supported by her track record of leading successful regulatory submissions resulting in multiple FDA and EMA approvals.

“I look forward to executing and refining Anavex’s clinical, regulatory and operational strategy and working closing with the regulatory authorities that will help advance the development of our compounds,” stated Dr. Kellmeyer. “We believe in our core mission in developing innovative oral therapies for individuals living with neurological disorders and central nervous system diseases. With a strong cash balance and no long-term debt, we will continue to focus on our lead candidate, oral blarcamesine, in early Alzheimer’s disease, and begin to build out the appropriate team while creating long-term shareholder value.”

The Company expects to file a Form 12b-25 to extend the filing date of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, as it is currently not expected to meet the due date for such report under the rules of the Securities and Exchange Commission (the “SEC”). The Company intends to host a conference call and webcast that will provide further information regarding its second quarter 2026 financial results and the filing of its Form 10-Q at a later date.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders. Further information is available at www.anavex.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Investor Relations & Media Contact:

SCR Partners, LLC
Alex Arzeno
Tel: 203-550-3972
Email: alex@scr-ir.com

Tripp Sullivan
Tel: 615-942-7077
Email: tsullivan@scr-ir.com

Company Contact:

Sandra Boenisch
Principal Financial Officer
Anavex Life Sciences Corp.
Tel: 1-844-689-3939
Email: ir@anavexcorp.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the interim CEO of Anavex (AVXL) as of May 6, 2026?

Dr. Terrie Kellmeyer is interim CEO, appointed May 6, 2026. According to the company, she is a senior pharmaceutical executive with nearly 30 years of experience in clinical development, regulatory affairs, quality and medical operations and will lead the company’s clinical programs.

Why did Anavex (AVXL) file a Form 12b-25 on May 6, 2026?

Anavex plans to file a Form 12b-25 to extend its Form 10-Q filing deadline. According to the company, it currently does not expect to meet the SEC due date for the quarter ended March 31, 2026.

What is Anavex’s near-term clinical focus under interim CEO Terrie Kellmeyer?

The company will prioritize advancing its clinical and regulatory strategy for CNS programs, especially oral blarcamesine. According to the company, efforts will focus on interactions with FDA and EMA to progress development.

Does Anavex (AVXL) have material debt or liquidity concerns reported May 6, 2026?

According to the company, Anavex has a strong cash balance and no long-term debt. The company cited this position while describing continued focus on its lead candidate and building the development team.

Will Anavex (AVXL) provide more details on Q2 2026 results and the 10-Q filing?

Yes. The company intends to host a conference call and webcast to provide additional information on second quarter 2026 financial results and the Form 10-Q filing at a later date, according to the company’s announcement.